Firm expands bioanalytical and immunoassay capabilities into the U.S.

ICON acquired Prevalere Life Sciences for an initial cash payment of $35M. If certain performance milestones are achieved, an additional $8.2M may be paid out.

Prevalere provides bioanalytical and immunoassay laboratory services to the biotechnology and pharmaceutical industries and operates from a 49,000 square foot facility in Whitesboro, NY. The acquisiton of Prevalere will complement ICON’s existing European-based bioanalytical lab capabilities in Manchester, England.

Previous articleValeant Pharmaceuticals Acquires DermaTech for $12.6M
Next articlePfizer Launches New Global Research Unit